MARINOMED BIOTECH AG INH.
Research MARINOMED BIOTECH AG INH. (93Z) on Bullrun: market cap EUR 17.59M, P/E 0.9. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker93Z
- ExchangeF
- CountryAustria
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 17.59M
- P/E0.9
- Financial periodFY2024
- RevenueEUR 4.75M
- Revenue growth-47.6%
- Net income-EUR 15.42M
- Free cash flow-EUR 2.40M
- Gross margin20.6%
Valuation Snapshot
latest market cap is EUR 17.59M; P/E is 0.9.
About MARINOMED BIOTECH AG INH.
Marinomed Biotech AG operates as a biopharmaceutical company in Austria, other European countries, and internationally. Its lead products include Budesolv for the treatment of allergic rhinitis in late-stage clinical development; and Tacrosolv for the treatment of inflammatory eye diseases in Phase II clinical studies. The company also develops Satiasolv for pain immune reactions in the preclinical development phase. In addition, it provides Solv4U for formulation development and biopharmaceutical testing services.
Frequently asked questions
What is MARINOMED BIOTECH AG INH.'s market cap?
MARINOMED BIOTECH AG INH.'s market capitalization is EUR 17.59M.
What is MARINOMED BIOTECH AG INH.'s P/E ratio?
MARINOMED BIOTECH AG INH.'s price-to-earnings (P/E) ratio is 0.9.
What does MARINOMED BIOTECH AG INH. do?
Marinomed Biotech AG operates as a biopharmaceutical company in Austria, other European countries, and internationally. Its lead products include Budesolv for the treatment of allergic rhinitis in late-stage clinical development;